17,261 trials
HIV Infections
Primary: The Percentage of Participants Who Report Willingness to Use the Study Regimen, Take up PrEP, and Remain on PrEP as Part of a Comprehensive Prevention Package — 148…
Heart Failure With Preserved Ejection Fraction (HFpEF)
Primary: Change From Baseline at Week 32 in Peak V02 Consumption in Verinurad + Allopurinol Compared to Placebo (ANCOVA Model) — 0.27; 0.37 mL/kg/min — p=0.862
COVID-19
Primary: Percentage of Participants With Disease Progression Using National Institute of Allergy and Infectious Diseases (NIAID) 8-point Ordinal Scale at Day 14 — 9.8; 11.6…
Biliary Tract Cancer
Primary: Progression Free Survival (PFS) — 7.92; 8.35 Months
Anal Canal Squamous Cell Carcinoma · Stage I Anal Cancer AJCC v8 · Stage II Anal Cancer AJCC v8
Primary: Acute Toxicity — 2 Participants
Leukemia · Acute Myeloid Leukemia · Acute Lymphocytic Leukemia
Primary: Non-Relapse Mortality Rate (NRM) — 2; 8 Participants
Grade IV Glioma · Grade IV Astrocytoma · Glioblastoma Multiforme
Primary: Progression of Disease — 14 Participants
Acute Biphenotypic Leukemia · Acute Myeloid Leukemia · de Novo Myelodysplastic Syndrome
Primary: Phase 1: Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) of Mitoxantrone — 18 mg/m^2
Alcohol Use Disorder · Post Traumatic Stress Disorder
Primary: Number of Drinks Per Day — 4.4885; 5.3623 drinks/day
Tuberculosis
Primary: Safety of Escalating Doses of Pravastatin as Assessed by Number of Adverse Events — 8; 4 AEs Grade 3 or Higher
Nasopharyngeal Carcinoma
Primary: Best Overall Response Rate (ORR) — 0.0 percentage of participants
Graft vs Host Disease
Primary: Percentage of Participants With Overall Response (OR) — 64.7; 68.8; 57.1 percentage of participants
Missed Abortion · Anembryonic Pregnancy · Non-Viable Pregnancy
Primary: Percentage of Participants Recruited to Study Protocol — 37.5 percentage of participants
Multiple Myeloma
Primary: Overall Response Rate (ORR) in Participants Treated at the (Maximum Tolerated Dose) MTD, as Assessed Using International Myeloma Working Group (IMWG) Criteria — 40…
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive · Acute Biphenotypic Leukemia · Acute Leukemia
Primary: Time to Engraftment — 2; 1; 1; 1 Participants